Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study

Abstract Background The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID-19 treatments in Scotland. Methods Ret...

Full description

Bibliographic Details
Published in:	BMC Infectious Diseases
Main Authors:	Myriam Drysdale, Holly Tibble, Vishal Patel, Daniel C. Gibbons, Emily J. Lloyd, William Kerr, Calum Macdonald, Helen J. Birch, Aziz Sheikh
Format:	Article
Language:	English
Published:	BMC 2024-07-01
Subjects:	COVID-19 Sotrovimab Molnupiravir Nirmatrelvir/ritonavir Omicron BA.1 Omicron BA.2
Online Access:	https://doi.org/10.1186/s12879-024-09576-7

Similar Items

Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England
by: Vishal Patel, et al.
Published: (2024-04-01)

Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
by: Alwaleed Behzad, et al.
Published: (2024-02-01)

Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
by: Ahmed Zaqout, et al.
Published: (2022-11-01)

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks
by: Tommaso Manciulli, et al.
Published: (2022-04-01)

Safety and Efficacy of Outpatient Treatments for COVID-19: Real-Life Data from a Regionwide Cohort of High-Risk Patients in Tuscany, Italy (the FEDERATE Cohort)
by: Tommaso Manciulli, et al.
Published: (2023-02-01)

Clinical severity of Delta and 3 different Omicron sublineages in patients hospitalized because of COVID-19 in a Swiss tertiary center
by: Erol Orel, et al.
Published: (2024-11-01)

Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA.2 versus BA.1: a multicentre, retrospective cohort study
by: Carson K. L. Lo, et al.
Published: (2024-01-01)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
by: Federico Baldi, et al.
Published: (2023-01-01)

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine
by: Yu X, et al.
Published: (2024-09-01)

A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir
by: Jiantao Zheng, et al.
Published: (2023-06-01)

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
by: José Luis Piñana, et al.
Published: (2023-10-01)

Outcomes of pregnant women exposed to Sotrovimab for the treatment of COVID-19 in the BA.1 Omicron predominant era (PRESTO)
by: Jessica J. Tuan, et al.
Published: (2023-04-01)

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
by: Yue Yat Harrison Cheung, et al.
Published: (2024-01-01)

Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals
by: Andrea Giacomelli, et al.
Published: (2024-06-01)

Differential immunity induced by Omicron sublineages in naïve and vaccine breakthrough infections
by: Noah Brazer, et al.
Published: (2025-07-01)

A comparative study on epidemiological characteristics, transmissibility, and pathogenicity of three COVID-19 outbreaks caused by different variants
by: Chan Liu, et al.
Published: (2023-09-01)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01)

The presence of neutralizing antibodies against omicron subvariants among a vaccinated cohort at one year after the first dose of vaccination in Malaysia
by: Eida Nurhadzira Muhammad, et al.
Published: (2025-06-01)

Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
by: Daniele Focosi, et al.
Published: (2022-08-01)

Epidemiology and Clinical Characteristics of Laboratory-Confirmed COVID-19 and Influenza Infections in Children: A 2015–2024 Study in Taiwan
by: Hao-Yuan Lee, et al.
Published: (2025-02-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Chih-Cheng Lai, et al.
Published: (2022-08-01)

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
by: Carsten Schade Larsen
Published: (2022-09-01)

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
by: Fatemeh Saheb Sharif-Askari, et al.
Published: (2024-10-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Uninvited Guest: Arrival and Dissemination of Omicron Lineage SARS-CoV-2 in St. Petersburg, Russia
by: Anna Gladkikh, et al.
Published: (2022-08-01)

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality
by: Jialiang Jiang, et al.
Published: (2025-02-01)

The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer
by: Wan-Hsuan Hsu, et al.
Published: (2024-08-01)

Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
by: Yue Yat Harrison Cheung, et al.
Published: (2024-06-01)

The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
by: Vasilios Petrakis, et al.
Published: (2023-04-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

SARS-CoV-2 Omicron BA.4/BA.5 Mutations in Spike Leading to T Cell Escape in Recently Vaccinated Individuals
by: Maarten E. Emmelot, et al.
Published: (2022-12-01)

Comparing COVID-19 severity in patients hospitalized for community-associated Delta, BA.1 and BA.4/5 variant infection
by: Maja Sočan, et al.
Published: (2024-02-01)

Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
by: Guang‐Bin Chen, et al.
Published: (2024-06-01)

Efficacy and Safety of Sotrovimab Versus Oral Antiviral for Early Treatment in High-Risk Patients in Omicron Era: A Multicenter Retrospective Study
by: Antonio Russo, et al.
Published: (2025-02-01)